Advertisement

Pharmacovigilance of Herbal and Traditional Medicines

  • Li Zhang
Protocol
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

This chapter first differentiates the concepts of traditional/complementary medicine and their products. It then briefly introduces the supervision and management systems of the China Food and Drug Administration and the differences between conventional medicine and traditional/complementary medicine products, taking drugs used in traditional Chinese medicine as an example. The chapter analyzes and discusses the global use of and regulatory environment for complementary and integrated medicine, and reviews the current methodological approaches to pharmacovigilance for herbal drugs and traditional medicines. Therefore throughout this chapter are showcased the challenges associated with such products and their rational uses, and the imperfections in the global supervision of such medicines in terms of both the methodology behind monitoring by the spontaneous reporting system (SRS) and additional pharmacovigilance. Finally, suggestions are proposed for measures to enhance pharmacovigilance of herbal and traditional medicines.

Key words

Pharmocovigilance Herbal and traditional medicine (H&TM) Traditional Chinese medicine (TCM) Spontaneous reporting system (SRS) Active surveillance Post-authorization safety study (PASS) 

References

  1. 1.
    WHO (2013) WHO traditional medicine strategy 2014–2023. http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en/. Accessed 20 Jun 2017
  2. 2.
    WHO Traditional medicine: definitions. http://www.who.int/medicines/areas/traditional/definitions/en/. Accessed 20 Jun 2017
  3. 3.
    Ramzan I, Linek EV (2015) International regulatory status of phytotherapies. Phytothérapie 24:593–634Google Scholar
  4. 4.
    Pharmacopoeia Commission of the Ministry of Health of the People’s Republic of China (2015) Pharmacopoeia of the People’s Republic of China, vol 1. China Medical Science Press, BeijingGoogle Scholar
  5. 5.
  6. 6.
    Gao X, Zhong G (2013) Traditional Chinese pharmacy, 2nd edn. Beijing People Medical Publishing House, BeijingGoogle Scholar
  7. 7.
    FDA (2016) Dietary supplement products & ingredients. https://www.fda.gov/Food/DietarySupplements/ProductsIngredients/default.htm. Accessed 23 Jun 2017
  8. 8.
    FDA (2015) Current good manufacturing practices (CGMPs) for dietary supplements. http://www.fda.gov/Food/GuidanceRegulation/CGMP/ucm079496.htm. Accessed 23 Jun 2017
  9. 9.
  10. 10.
    Government of Canada (2017) Food and drug regulations. http://laws.justice.gc.ca/eng/regulations/C.R.C.,_c._870/index.html. Accessed 23 Jun 2017
  11. 11.
    Government of Canada (2015) Natural and non-prescription health products. https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription.html. Accessed 23 Jun 2017
  12. 12.
    EMA (2004) Directive 2004/24/EC of the European parliament and of the council. http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2004_24/dir_2004_24_en.pdf. Accessed 23 Jun 2017
  13. 13.
    Zhang L, Wong YL, He Y et al (2014) Pharmacovigilance in China: current situation, successes and challenges. Drug Saf 37(10):765–770. https://doi.org/10.1007/s40264-014-0222-3 CrossRefPubMedGoogle Scholar
  14. 14.
    Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 4(4):177. https://doi.org/10.3389/fphar.2013.00177 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    The State Administration of Traditional Chinese Medicine (2011) China. http://www.satcm.gov.cn/1987-2010/start.htm. Accessed 20 Jun 2016
  16. 16.
    Friesen D (2013) Traditional Chinese Medicine: business blockbuster or false fad? CKGSB Knowledge. http://knowledge.ckgsb.edu.cn/2013/01/08/china/traditional-chinese-medicine-business-blockbuster-or-false-fad/. Accessed 23 Jun 2017
  17. 17.
    Lindstrom A, Ooyen C, Lynch ME et al (2014) Sales of herbal dietary supplements increase by 7.9% in 2013, marking a decade of rising sales. HerbalGram 103:52–56Google Scholar
  18. 18.
    NIH (2014) Frequently asked questions: name change. https://nccih.nih.gov/news/name-change-faq. Accessed 23 Jun 2017
  19. 19.
    UMC (2000) Safety monitoring of medicinal products. https://www.who-umc.org/media/1703/24747.pdf. Accessed 23 Jun 2017
  20. 20.
    Barnes J (2003) Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 26(12):829–851CrossRefGoogle Scholar
  21. 21.
  22. 22.
    Edwards IR, Ericsson J (2006) Spontaneous reporting of herbal ADRs: the global experience. Drug Saf 29(4):351–352Google Scholar
  23. 23.
    Farah MH, Olsson S, Bate J et al (2006) Botanical nomenclature in pharmacovigilance and a recommendation for standardization. Drug Saf 29(11):1023–1029CrossRefGoogle Scholar
  24. 24.
    Bate A, Ericsson J, Farah M (2006) International data mining for signals of herbal ADRs. Drug Saf 29(4):353–354Google Scholar
  25. 25.
    Farah M, Meyboom R, Ploen M (2008) Acute hypersensitivity reactions to Andrographis paniculata containing products, as reported in international pharmacovigilance. Drug Saf 31(10):885–960Google Scholar
  26. 26.
    CFDA (2016) 2015 Annual report for National ADR Monitoring. http://www.sfda.gov.cn/WS01/CL0051/158941.html. Accessed 25 Jun 2017
  27. 27.
    Zhang L, Yan J, Liu X et al (2012) Pharmacovigilance practice and risk control of traditional Chinese medicine drugs in China: current status and future perspective. J Ethnopharmacol 140(3):519–525CrossRefGoogle Scholar
  28. 28.
    Kalaiselvan V, Saurabh A, Kumar R et al (2015) Adverse reactions to herbal products: an analysis of spontaneous reports in the database of the Pharmacovigilance Programme of India. J Herbal Med 5:48–54CrossRefGoogle Scholar
  29. 29.
    Sareeya W, Wimon S, Vorasith S et al (2014) Signal detection for Thai traditional medicine: examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk. Regul Toxicol Pharmacol 70:407–412CrossRefGoogle Scholar
  30. 30.
    Denney CE, Tsourounis C, Horn AJ (2005) Dietary supplement-related adverse events reported to the California poison control system. Am J Health Syst Pharm 62:1476–1482CrossRefGoogle Scholar
  31. 31.
    Gryzlak BM, Wallace RB, Zimmerman MB et al (2007) National surveillance of herbal dietary supplement exposures: the poison control center experience. Pharmacoepidemiol Drug Saf 16:947–957CrossRefGoogle Scholar
  32. 32.
    Shaw D, Graeme L, Pierre D et al (2012) Pharmacovigilance of herbal medicine. J Ethnopharmacol 140(3):513–518CrossRefGoogle Scholar
  33. 33.
    Gardiner P, Sarma D, Low DT et al (2008) The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiol Drug Saf 17:962–970CrossRefGoogle Scholar
  34. 34.
    Edwards IR (2014) Adverse drug effects and their clinical management: a personal view. Drug Saf 37:383–390. https://doi.org/10.1007/s40264-014-0167-6 CrossRefPubMedGoogle Scholar
  35. 35.
    WHO (2009) Report of the regional meeting, World Health Organization. The use of herbal medicines in primary health care. World Health Organization, Regional Office for South-East Asia, IndiaGoogle Scholar
  36. 36.
    McRae CA, Agarwal K, Mutimer D et al (2012) Hepatitis associated with Chinese herbs. Eur J Gastroenterol Hepatol 14:559–562CrossRefGoogle Scholar
  37. 37.
    Shaw D (2010) Investigation of liver toxicity of Chinese herbal medicine: pilot case-control study. Drug Saf 33:918–919Google Scholar
  38. 38.
    Chuang CH, Chang PJ, Hsieh WS et al (2009) Chinese herbal medicine use in Taiwan during pregnancy and the postpartum period: a population-based cohort study. Int J Nurs Stud 46:787–795CrossRefGoogle Scholar
  39. 39.
    Pal SN, Wallberg M, Coulter D et al (2010) Cohort event monitoring: a WHO strategy to complement spontaneous reporting systems. Drug Saf 33(10):939Google Scholar
  40. 40.
    Saokaew S, Suwankesawong W, Permsuwann U et al (2011) Safety of herbal products in Thailand. Drug Saf 34:339–350CrossRefGoogle Scholar
  41. 41.
    Deng PY, Li QN, Zhu YZ (2005) An analysis of ADR of Puerarin Injection and related risk factors. Chin J Pharmacoepidemiol 14(1):14–24Google Scholar
  42. 42.
    Deng PY, Zhang L (2008) The post-marketing safety monitoring of puerarin injection (1). Chin J Pharamacovigilance 5(3):136–143Google Scholar
  43. 43.
    Deng PY, Zhang L (2008) The post-marketing safety monitoring of puerarin injection (2). Chin J Pharamacovigilance 5(4):208–211Google Scholar
  44. 44.
    Deng JX, Yu JY, Yuan ZM (2012) Post-marketing safety reevaluation of Shengmai Injection. China Licensed Pharmacist 9(12):11–16Google Scholar
  45. 45.
    Yu JY, Deng JX, Ma GY et al (2014) Post-marketing safety reassessment of Shenqifuzheng Injection. China Licensed Pharmacist 11(1):13–15Google Scholar
  46. 46.
    Du W, Levine M, Wang L et al (2007) Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai. Can J Clin Pharmacol 14:e40–e44PubMedGoogle Scholar
  47. 47.
    Guo DH, Chen C, Ma L et al (2014) Analysis and evaluation of the active monitoring data from five hospitals by ADE warning systems for hospitalized patients. Chin J Drug Appl Monit 11(6):368–371Google Scholar
  48. 48.
    Yang HC, Iqbal U, Nguyen PA et al (2016) An automated technique to identify potential inappropriate traditional Chinese medicine (TCM) prescriptions. Pharmacoepidemiol Drug Saf 25(4):422–430. https://doi.org/10.1002/pds.3976 CrossRefPubMedGoogle Scholar
  49. 49.
    World Health Organisation (2004) WHO guidelines on safety monitoring of herbal. Medicines in pharmacovigilance systems. WHO, WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems, Geneva. http://apps.who.int/medicinedocs/documents/s7148e/s7148e.pdf. Accessed 20 Apr 2015
  50. 50.
    Simon LS (2002) Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis 61.(Suppl.2:ii88–ii89CrossRefGoogle Scholar
  51. 51.
    Buch MH, Aletaha D, Emery P et al (2011) Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 70:886–890CrossRefGoogle Scholar
  52. 52.
    Walji R, Boon H, Barnes J et al (2009) Adverse event reporting for herbal medicines: a result of market forces. Healthcare Policy 4(4):77–90PubMedPubMedCentralGoogle Scholar
  53. 53.
    Ministry of Health and China Food and Drug Administration (2011) Adverse drug reaction reporting and monitoring provision. http://app1.sfda.gov.cn/WS01/CL0288/62621.html. Accessed 7 Jun 2017
  54. 54.
    CFDA (2009) Notice for doing well in the reevaluation of TCM injections. http://www.sda.gov.cn/WS01/CL0055/39880.html. Accessed 20 Jun 2017
  55. 55.
    CFDA (2010) Notice for publication the 7 principals for technical guideline on TCM injection safety re-evaluation concerning production process, quality control clinical study and so on. http://www.sda.gov.cn/WS01/CL0055/54917_2.html. Accessed 20 Jun 2017
  56. 56.
    Liao X, Xie Y, Yang W, Chang Y (2014) The significance of introducing registry study in the post marketing safety research for Chinese medicine pharmacy. Chin J Integr Tradit West Med 34(3):261–266CrossRefGoogle Scholar
  57. 57.
    Xia L, Li JH, Zhao K et al (2015) Incidence and in-hospital mortality of acute aortic dissection in China: analysis of China Health Insurance Research (CHIRA) Data 2011. Geriatr Cardiol 12(5):502–506Google Scholar
  58. 58.
    Zhang Y, Cheng Y, Feng Y et al (2015) A systematic review of publications based on electronic medical records or medicare systems and related databases in China. ISPE’s 9th Asian Conference on Pharmacoepidemiology, Bangkok, ThailandGoogle Scholar
  59. 59.
    Chinese Medicine Board of Australia (CMBA) (2014) About us. http://www.chinesemedicineboard.gov.au/About.aspx. Accessed 20 Jun 2017
  60. 60.
    CMBA (2012) Chinese Medicine Board Newsletter, Issue 1, October, 2012Google Scholar
  61. 61.
    CMBA (2015) Guidelines for safe Chinese herbal medicine practice. http://www.chinesemedicineboard.gov.au/Codes-Guidelines/Guidelines-for-safe-practice.aspx. Accessed 20 Jun 2017
  62. 62.
    Guo D, Wu W, Ye M et al (2015) A holistic approach to the quality control of traditional Chinese medicines. Science 347(6219 Suppl):S29–S31Google Scholar
  63. 63.
    Williamson E, Chan K, Xu Q et al (2015) Evaluating the safety of herbal medicines: integrated toxicological approaches. Science 347(6219 Suppl):S47–S49Google Scholar
  64. 64.
    Yu Y, Hu S, Li G et al (2014) Comparative effectiveness of Di’ao Xin Xue Kang capsule and compound Danshen tablet in patients with symptomatic chronic stable angina. Sci Rep 14(4):7058. https://doi.org/10.1038/srep07058 CrossRefGoogle Scholar
  65. 65.
    Zhang L, Yang XH, Deng YY (2009) Liver damage related to Polygonum multiflorumand its preparations: domestic literature review and analysis. China J Chin Mater Med 34(18):2414–2418Google Scholar
  66. 66.
    Skalli S, Bencheikh RS (2015) Pharmacovigilance of herbal medicines in Africa: questionnaire study. J Ethnopharmacol 171:99–108. https://doi.org/10.1016/j.jep.2015.05.033 CrossRefPubMedGoogle Scholar
  67. 67.
    Chen SP, Ng SW, Poon WT et al (2012) Aconite poisoning over 5 years: a case series in Hong Kong and lessons towards herbal safety. Drug Saf 35(7):575–587. https://doi.org/10.2165/11597470-000000000-00000 CrossRefPubMedGoogle Scholar
  68. 68.
    Pratt N, Chan EW, Choi NK et al (2015) Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol Drug Saf 24(8):858–864CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Li Zhang
    • 1
  1. 1.Department of Scientific ResearchDongfang Hospital, Beijing University of Chinese MedicineBeijingPeople’s Republic of China

Personalised recommendations